Table 2. Number and SIRs of second tumours in urinary bladder cancer patients.
|
Women
|
Men
|
|||
|---|---|---|---|---|
| Second cancer type | N | SIR (95% CI) | N | SIR (95% CI) |
| Recurrent neoplasms | ||||
| Urinary bladder | 132 | 10.5 (8.87–12.5) | 501 | 5.66 (5.19–6.19) |
| Renal pelvis | 48 | 40.1 (30.0–53.5) | 154 | 34.5 (29.2–40.7) |
| Smoking-related cancer sites (excluding recurrent neoplasms) | ||||
| Upper aerodigestive tract | 6 | 0.73 (0.33–1.63) | 70 | 1.28 (1.01–1.61) |
| Oesophagus | 7 | 4.53 (2.16–9.51) | 47 | 0.87 (0.66–1.16) |
| Stomach | 19 | 0.95 (0.60–1.49) | 188 | 1.04 (0.90–1.20) |
| Anus | 2 | 1.36 (0.34–5.44) | 6 | 1.23 (0.55–2.76) |
| Pancreas | 42 | 1.54 (1.14–2.09) | 120 | 1.23 (1.02–1.47) |
| Nose | 1 | 0.38 (0.05–2.73) | 7 | 1.13 (0.54–2.38) |
| Larynx | 1 | 0.83 (0.12–5.89) | 48 | 1.35 (1.02–1.79) |
| Lung | 115 | 3.32 (2.76–3.99) | 645 | 2.00 (1.85–2.17) |
| Cervix | 13 | 0.41 (0.24–0.71) | ||
| Renal parenchyma | 16 | 0.60 (0.37–0.98) | 91 | 1.38 (1.12–1.69) |
| Any smoking-related | 222 | 1.58 (1.38–1.80) | 1222 | 1.50 (1.42–1.59) |
| Non-smoking-related cancer sites | ||||
| Salivary glands | 3 | 2.16 (0.70–6.71) | 7 | 1.35 (0.64–2.85) |
| Small intestine | 5 | 0.82 (0.34–1.97) | 32 | 1.81 (1.27–2.56) |
| Colon | 95 | 1.76 (1.44–2.15) | 352 | 1.21 (1.09–1.34) |
| Rectum | 46 | 1.67 (1.25–2.24) | 187 | 1.22 (1.06–1.41) |
| Liver | 34 | 2.06 (1.47–2.88) | 112 | 1.96 (1.63–2.36) |
| Breast | 195 | 0.98 (0.85–1.13) | 5 | 0.95 (0.39–2.29) |
| Endometrium | 52 | 4.83 (3.68–6.34) | ||
| Ovary | 31 | 0.71 (0.50–1.01) | ||
| Other female genital | 6 | 2.04 (0.91–4.54) | ||
| Prostate | 1454 | 1.41 (1.34–1.49) | ||
| Testis | 2 | 0.98 (0.24–3.91) | ||
| Other male genital | 11 | 0.81 (0.45–1.47) | ||
| Melanoma | 23 | 2.61 (1.74–3.93) | 107 | 1.18 (0.98–1.43) |
| Skin, squamous cell | 53 | 1.64 (1.26–2.15) | 272 | 1.30 (1.15–1.47) |
| Eye | 5 | 1.98 (0.82–4.76) | 13 | 3.62 (2.10–6.25) |
| Nervous system | 24 | 1.24 (0.83–1.85) | 70 | 26.3 (20.8–33.3) |
| Thyroid gland | 6 | 0.72 (0.32–1.60) | 19 | 1.69 (1.07–2.65) |
| Endocrine glands | 27 | 1.87 (1.28–2.72) | 34 | 1.72 (1.23–2.41) |
| Bone | 3 | 0.40 (0.13–1.25) | ||
| Connective tissue | 8 | 2.18 (1.09–4.37) | 27 | 1.30 (0.89–1.90) |
| Hodgkin disease | 2 | 2.54 (0.63–10.2) | 9 | 6.92 (3.60–13.3) |
| Non-Hodgkin lymphoma | 35 | 1.36 (0.98–1.90) | 110 | 0.97 (0.80–1.17) |
| Myeloma | 6 | 0.41 (0.18–0.92) | 58 | 9.97 (7.70–12.9) |
| Leukaemia | 36 | 4.53 (3.27–6.28) | 121 | 1.16 (0.97–1.38) |
| Any non-smoking related | 653 | 1.38 (1.28–1.49) | 3005 | 2.85 (2.75–2.95) |
| Any site | 1138 | 1.91 (1.80–2.03) | 5060 | 2.77 (2.69–2.84) |
Abbreviations: CI=confidence interval; SIR=standardised incidence ratio.
Only tumours diagnosed at least one year apart were included in the calculations.
Bold type represents a significant increase at the 5% confidence level.